Annual report pursuant to Section 13 and 15(d)

Acquisition (Tables)

v3.3.1.900
Acquisition (Tables)
12 Months Ended
Nov. 30, 2015
Business Combinations [Abstract]  
Summary of Fair Value of Consideration for the Acquisition

The following summarizes the fair value of the consideration for the Acquisition:

 

Consideration

  

Cash

   $ 375,374   

Assumed liabilities of seller

     1,073,898   

Note payable to seller

     1,300,000   

Prepaid expense paid to seller by purchaser

     104,000   
  

 

 

 

Consideration

   $ 2,853,272   
  

 

 

 
Summary of Allocation of Total Purchase Price for the Acquisition

The following summarizes the allocation of the total purchase price for the Acquisition:

 

Inventory

   $ 529,097   

Tooling molds

     35,353   

License agreement

     470,000   

Customer relationships

     41,000   
  

 

 

 

Total identifiable net assets acquired

     1,075,450   
  

 

 

 

Goodwill

   $ 1,777,822   
  

 

 

 
Summary of Unaudited Pro Forma Combined Statement of Operations

Unaudited Pro Forma Combined Statement of Operations

As of November 30, 2015

 
     Company
Historical
     Prepacyte CB
(Acquired)
Historical
     Pro Forma
Combined
 

Revenue

   $ 20,620,138         1,146,140       $ 21,766,278   

Net Income

     8,106,343         299,626       $ 8,405,969   

Income per share:

        

Basic

   $ 0.85       $ 0.03       $ 0.88   
  

 

 

    

 

 

    

 

 

 

Diluted

   $ 0.83       $ 0.03       $ 0.86   
  

 

 

    

 

 

    

 

 

 

 

Unaudited Pro Forma Combined Statement of Operations

As of November 30, 2014

 
     Company
Historical
     Prepacyte CB
(Acquired)
Historical
     Pro Forma
Combined
 

Revenue

   $ 20,126,546         1,111,720       $ 21,238,266   

Net Income

     553,623         296,465         850,088   

Income per share:

        

Basic

   $ 0.05       $ 0.03       $ 0.08   
  

 

 

    

 

 

    

 

 

 

Diluted

   $ 0.05       $ 0.03       $ 0.08